Dabigatran versus warfarin in patients with atrial fibrillation.
Tomoda
Haruo
H
D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001562:Benzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D000069604:Dabigatran; D004359:Drug Therapy, Combination; D006801:Humans; D009203:Myocardial Infarction / Q000453:epidemiology / Q000517:prevention & control; D015539:Platelet Activation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D001562:Benzimidazoles; D010975:Platelet Aggregation Inhibitors; D011725:Pyridines; D014859:Warfarin; D000069604:Dabigatran; D001241:Aspirin